Hong Kong, Shanghai, & Florham Park, NJ — Friday, June 18, 2021: HUTCHMED (China) Limited (“HUTCHMED” or the “Company”) (Nasdaq/AIM: HCM) today filed the Post Hearing Information Pack (the “PHIP”) with the Stock Exchange of Hong Kong Limited (“SEHK”) in connection with a proposed listing (the “Listing”) of its ordinary shares, par value US$0.10 per share (“Shares”), on the Main Board of the Hong Kong Stock Exchange and concurrent global offering of Shares (the “Global Offering”).
The PHIP contains updated disclosure of certain information previously disclosed in the Company’s annual report on Form 20-F for the year ended December 31, 2020 filed on March 4, 2021 (the “2020 Annual Report”) and supplemental and additional descriptions of certain aspects of the Company’s business and financial information as required by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, the latter of which is available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3226C_2-2021-6-18.pdf. This disclosure should be read in conjunction with the Company’s 2020 Annual Report and final results announcement published on March 4, 2021. The unaudited condensed consolidated interim financial information of the Company as of and for the three months ended March 31, 2021 are available for viewing at http://www.rns-pdf.londonstockexchange.com/rns/3226C_1-2021-6-18.pdf.
There is no assurance as to if or when such Listing will take place. This announcement is neither an offer to sell nor a solicitation of an offer to buy, nor shall there be any offer, solicitation or sale of the Company’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018).
HUTCHMED (Nasdaq/AIM: HCM) (formerly Hutchison China MediTech) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,300 personnel has advanced ten cancer drug candidates from in-house discovery into clinical studies around the world, with its first two oncology drugs now approved and launched. For more information, please visit: www.hutch-med.com or follow us on LinkedIn.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect HUTCHMED’s current expectations regarding future events. Forward-looking statements involve risks and uncertainties. Factors that may cause such a difference include risks and uncertainties related to completion of the SEHK’s review of the Company’s listing application and completion of the Global Offering (including the terms of the Global Offering), market conditions, the satisfaction of customary closing conditions related to the Global Offering, whether and the degree to which the Company will continue to benefit from CK Hutchison Holding’s support, and the Company’s ability to progress the development of its drug candidates and successfully commercialize them. More information about the risks and uncertainties faced by the Company will be contained or incorporated by reference in the preliminary prospectus filed with the SEHK and preliminary prospectus supplement filed with the SEC, in each case related to the Global Offering, when completed. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the SEHK, SEC and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
No prospectus required for the purposes of Regulation (EU) 2017/1129 (“EU Prospectus Regulation”) or Regulation (EU) 2017/1129 (as it forms part of retained EU law as defined in the European Union (Withdrawal) Act 2018) (“UK Prospectus Regulation”) or admission document (as defined in the AIM Rules for Companies published by the London Stock Exchange plc) will be made available in connection with the matters contained in this announcement.
No money, securities or other consideration is being solicited, and, if sent in response to the information contained in this announcement, will not be accepted.
This announcement is not directed to, or intended for distribution or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.
The distribution of this announcement into jurisdictions other than the United Kingdom may be restricted by law. Persons into whose possession this announcement come should inform themselves about and observe any such restrictions.
|Mark Lee, Senior Vice President||+852 2121 8200|
|Annie Cheng, Vice President||+1 (973) 567 3786|
|Brad Miles, Solebury Trout||+1 (917) 570 7340 (Mobile)
|Ben Atwell / Alex Shaw,
|+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
|Joseph Chi Lo, Brunswick||+852 9850 5033 (Mobile)|
|Zhou Yi, Brunswick||+852 9783 6894 (Mobile)
|Freddy Crossley /Atholl Tweedie,
Panmure Gordon (UK) Limited
|+44 (20) 7886 2500|